Human xenografts in nude mice have been extensively used to evaluate the efficacy of new anti-cancer drugs in a preclinical model, based on the notion that xenografts most closely mimic the situation in patients. The predictive value of the xenograft model was supported by the observation that generally good correlations between the response in patients and in xenografts of the same patients were found (Shorthouse et al., 1980 (Shorthouse et al., , 1982 Giovanella et al., 1983; Steel et al., 1983; Osieka, 1984; Mattern et al., 1988a; Fiebig et al., 1992) . However, since human tumours exhibit considerable heterogeneity of tumour biology and chemosensitivity between and within different tumour histologies, it has been proposed that a panel of tumours of various histological types should be used to predict the potential of new drugs (Fodstad et al., 1985; Winogard et al., 1988) . Only a few human soft-tissue sarcoma xenografts have been available for preclinically test and were not used in the drug screening programmes of the National Cancer Institute and the EORTC New Drug Development Office. We were able to establish a panel of more than 30 well-characterised human soft-tissue sarcoma cell lines as xenografts in nude mice. The poor clinical results of adjuvant and neoadjuvant chemotherapies in soft-tissue sarcomas of adults indicate a high degree of primary or a rapid development of secondary drug resistance to known drugs. In a preliminary series of investigations we were interested in evaluating whether the same degree of resistance would be expressed in soft-tissue sarcoma xenografts, providing a useful panel of tumours for preclinical tests. Therefore, the efficacies of ifosfamide (IFO) , doxorubicin (DOX), dacarbazine (DTIC) and cisplatin (DDP), four drugs with known clinical response rates, were tested in 16 sarcoma cell lines of the panel, in order to compare the patterns of sensitivities to the clinical data and to select sensitive and resistant cell lines for further investigations. Furthermore, two chemosensitive soft-tissue sarcoma cell lines were used to monitor the development of secondary drug resistance to IFO, DOX and DTIC in vivo. Materias and methods Sixteen grade III human soft-tissue sarcoma cell lines were used for the studies. Osieka et al. (1984) , who worked in parallel in the same institution on the identical strain of NMR1 nude mice, whereas for DOX and IFO we relied on data from our laboratory. According to these data, the 3.2 ± 0.1 4.9 ± 0.6 3.4 ± 0.5 3.4 ± 0.3 2.6 ± 0.5 6.0 ± 0.5 13.0 ± 5.6 5.7 ± 0.7 3.8 ± 0.8 2.7 ± 0.4 2.9 ± 0.2 2.4 ± 0.4
14.3 ± 4.6 Figure 4 and Table III . Interpreting the data one has to be aware that IFO induced significantly higher toxicity in terms of weight loss (Table II) and lethality ( Figure 1) To evaluate whether the efficacy of IFO might be overestimated because of its higher toxicity compared with the other tested drugs, dose-response curves were recorded for two chemosensitive sarcoma cell lines. Linear dose-response relationships were found for DOX and IFO (Figures 2 and 3) , whereas a non-linear relationship was observed for DTIC. In these experiments a dose of 275 mg kg-' IFO was found to be approximately isotoxic to 10 mg kg-' DOX, 200 mg kg-' DTIC and 6.6 mg kg-' DDP (Table II) (Blum, 1975; Pinedo & Verwey, 1985; Rosenberg et al., 1985) . Boven et al. (1989) tested seven human sarcoma lines in the xenograft system and found five to be responsive to DOX. According to Giuliani et al. (1981) , DOX was effective in one tested sarcoma line. Aamdal et al. (1986) reported an antitumour activity of DOX in 5 out of 12 sarcoma lines in a subrenal capsular assay. The total DOX doses in these studies were in the same range as in the present investigation, although some authors used a 2 day schedule. The use of a different end point, growth inhibition, in the work of Boven et al. (1989) or a different assay in the work of Aamdal et al. (1986) (Table III) , corresponding to an average growth delay of 84 days in one cell line and cure events in three cell lines, were observed. On the one hand, the efficacy of DTIC exceeded even the highest effects of IFO (Figure 4) in the four sensitive cell lines; on the other hand, in contrast to IFO, almost no effect was seen in all other cell lines.
DDP had the least effect of all tested drugs. Only one sarcoma cell line was moderately sensitive (Figure 4 , Table  III ). Tumour remissions were not observed. The low response rates of about 10% in clinical studies (Karakouis et al., 1979; Samson et al., 1979) are reflected in the xenograft data. Aamdal et al. (1986) (Table  IV) . IFO-resistant sarcomas were with one exception also resistant to all other drugs. DTIC was the only agent that was still effective in one IFO-resistant cell line. DOX was effective in two sarcoma lines, both of which were also highly responsive to IFO (Table III and Figure 4) . In IFO-resistant sarcoma lines DOX showed not even a moderate anti-tumour activity, indicating a complete cross-resistance in our data.
Combination therapy with IFO and DOX has in clinical studies induced response rates of between 24% and 36% (Dombernowsky et al., 1986; Wiltshaw et al., 1986; Schuitte et al., 1987) and has not convincingly demonstrated an advantage compared with monotherapy. The high degree of cross-resistance revealed by the experimental data is in agreement with this finding.
In the second part of the investigation the development of secondary drug resistance was monitored in two IFO-and DOX-sensitive sarcoma xenografts. Since drug delivery in vivo is inhomogeneous, the concentration of drug to which tumour ceUs are exposed and exposure time vary over a wide range, which results in a heterogeneous population of clones in the regrowing tumours. Environmental factors and interaction between host and tumour ceUs have also been shown to modify the development of resistance (Teicher et al., 1978; Moulder et al., 1991) . Therefore, human tumour xenografts represent a clinically relevant in situ model, which might provide additional information that is not attainable in vitro.
The response to DTIC decreased rapidly in both tested sarcoma cell lines ( Figure 5 ). After one pretreatment less than 50% of the initial efficacy and after 3-4 pretreatments no detectable response at all was observed. Pretreatments with DOX or IFO induced a less rapid development of secondary drug resistance ( Figure 5 ). Depending on the tumour line, 2-4 pretreatments were necessary to reduce the response to less than 50% of the initial response, and as many as 12 pretreatments with DOX had to be administered before DOX was without demonstrable efficacy ( Figure 5 ).
The selection pressure in these experiments was much lower for IFO and DOX (SGD = 5-8) than for DTIC . In similar experiments with a human malignant melanoma, DTIC (Osieka, 1984) was used at a considerably lower selection pressure (SGD = 5), resulting in still more than 50% of the initial efficacy after three pretreatments. In an epidermoid lung cancer cell line, successive treatments with actinomycin D, DDP and vincristine resulted in a 50% decrease of response after one, six and four pretreatments respectively (Mattern et al., 1988b) . In this study relatively low selection pressures (SGD = 2-3) were applied for all tested drugs, resulting in more than 25% of the initial response even after eight pretreatments. According to the available data the rapidity of development of secondary drug resistance in xenografts is mainly dependent on the extent of the selection pressure, whereas the tumour cell line and type of drug appear to be less important. However, too few data have been accumulated for a conclusive statement and none of the studies investigated the underlying mechanisms of drug resistance.
The pattern of response towards IFO, DOX, DTIC, and DDP in the tested panel of human soft-tissue sarcoma xenografts revealed a high degree of primary resistance and a rapid development of secondary resistance. This finding reflects clinical experience and indicates that a useful panel of tumours for further preclinical evaluation could be established. IFO was the most effective drug followed by DTIC and DOX. DDP showed almost no anti-tumour activity. One-third of the sarcoma lines were resistant to all tested drugs, with a high degree of cross-resistance between the drugs. Secondary drug resistance developed more slowly after DOX and IFO pretreatments at moderate selection pressure than after DTIC pretreatment at high selection pressure.
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